RVNC—Eylea is indeed a pertinent benchmark for the therapeutic side of the botulinum-toxin market. Dan Browne mentioned Eylea explicitly during the Apr 2018 Investor Day presentation (https://www.siliconinvestor.com/readmsg.aspx?msgid=31588927 ).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.